iFabric Corp.

I'm carrying on with a record year. So here to tell you more about that is Hilton Karon, CEO, Hilton Price, CFO, Giancarlo Beevis, COO. Before we get started, just so we're clear on the format, the gentlemen are going to provide a very brief overview of the quarter. And I think we have a lot of Q&A, so we'll just jump right into Q&A fairly quickly. I don't believe that we will be working off a presentation. Giancarlo Beevis

Good morning, everyone, and welcome. As I normally do, I'll start the webinar by saying that we put out a very comprehensive press release on the Q2 and six-month numbers and results. And the release, as well as the financial statements, management discussion analysis, can be viewed on our website at www.ifabriccorp.com. So I'm going to deal with what I consider the main or salient features of the results. I'll start with revenues. Q2 revenues came in at 9.6 million compared to 5.8 million in 2025, which was an increase of 3.8 million or 65%. There's one item I'd like to discuss here, and that is we provided $650,000 in advertising support to customers. And as required by IFRS, this is deducted from revenues. So in fact, our true amount invoice to customers was around $10.3 million. Hilton Price, Giancarlo Beevis Revenues, those came in at a record $37.1 million compared to $12.9 million in 2025, which is an increase of $24.2 million or 188%, an absolute record. I'd like to take a few moments to discuss the seasonal nature of our business. And in this regard, we have two kinds of programs, seasonal programs, and this would include products like swimwear, footwear. These are set programs and currently range in size from around 3 million to 8 million. They sell through fairly quickly, around two to three months. and these programs will normally ship in Q1 and Q4 and that's the reason why those are our biggest quarters historically. That may change in time as we get programs through the middle part of the year but at this point those programs generally go out in Q1 and Q4. Hilton Price, Giancarlo Beevis I don't believe we did any set programs. So if you look at the 65 increase growth year on year, that's a good indication of strong momentum in my mind. Gross margins. On the face of it, margins dropped from 37 last year to 30% in the current quarter. And here again, the $650,000 that we provided in advertising is deducted from margins. Because it's deducted from revenue, it flows down to margins. So the full 7% drop in margins is attributable to that $650,000 deduction for advertising. Going forward, we've taken the decision actually to provide less direct support to customers in favor of doing the advertising campaigns or the marketing ourselves in-house. We've hired specialists to do that. In our experience, retailers don't always spend the marketing dollars efficiently. I think actually we could do a better job. Hylton Karon, Hilton Price, Giancarlo Beevis Selling and administration expenses increased by 800k in the quarter compared to 20 to 5. Most of the increase is variable costs such as royalties and commissions as a result of the increased revenues. Although we did do a lot more traveling in the quarter and we have increased our staff complement year over year. So that is part of the increase, but the bulk of the increase is variable costs. and EBITDA. That came in at $715,000. Oh, let me just discuss one other thing before EBITDA. In the quarter, I'm pleased to report that we recognized $925,000 as sundry income in respect of the recovery of tariffs, Trump tariffs. This is net of our processing costs. The amount's been fully processed by US Customs. and to date we've already received 710,000 in cash. We've got 215 still to be received, which I believe will be received in the next quarter. EBITDA came in at $715,000, a turnaround of about a million from 2025. I was projecting break-even, so the tariff recovery obviously did provide us with some earnings. Hey, I'll take it. All gifts graciously received. EBITDA for the six months was $5.8 million compared to zero in 2025, and that's an absolute record for the company. I think that's it for the profit and loss account or the income statement. In terms of our balance sheet, our balance sheet has been beefed up by a very successful capital raise that we closed in June. We received and we banked net proceeds of around $21 million. and we finished the quarter with $25 million in cash after paying off our credit line and our working capital stood at around $45.1 million. So together with available credit lines of about $14 or $15 million between our trade credits and our regular bank line, I've calculated that we can push revenues well north of $100 million without the need for additional capital. Audit. I think that's all I really have to say. I'm happy to answer any questions.

Great. Thanks, Hilton. I had a bunch of questions come in in advance, so I'll start with those while the audience inputs any questions that they may have. So deposits paid to suppliers fell from 1.87 million in December to... Hilton Price, Giancarlo Beevis

Today, the deposits have grown to 5 million. So that's indicative of the fact that all the programs that we're expecting for later part of the year are starting to materialize and crystallize. I think the deposits figure will grow a bit more. Normally, we put down 25%. So if you times that number by four, that shows what's already in the books with more to come.

Yeah. Also, just to add to that is we've negotiated some better terms with our suppliers. So our deposit numbers are a little bit lower on the front end. So that's why you're seeing a little bit of a lower number on deposits.

Got it. And your 2025 segment note shows 49% gross margin in intimate apparels and 27.5% in intelligent fabrics. With IFTNA at 81% of revenue, that arithmetic gives 32% blended, which is what you reported. You guided to the high 30s. What were the two segment gross margins in the first half and what gets IFTNA above 27.5%?

Well, I did mention that 650,000, which is all IFTNA, so that did impact IFTNA's margins. Our target for blended is 35%. So intermittent apparel tends to be a bit higher. around about 49%, 50%. IFTNA generally around 30% because we're dealing with major retailers. We do a work of high volume, lower margin, and it depends on the product mix what the ultimate margin for the cord will be. If we do a high proportion of intimates, we should see better margins. If we do a high proportion of intelligent fabrics, the margins will drop.

Okay. And then talking about the marketing support to retailers, I think this is the first stated use of proceeds for the money that you raised. Should investors view this as a recurring cost of winning shelf space? What percentage of gross sales should we model for it going forward? And maybe you can just give a little bit more color on what that program is.

Hilton Price, Giancarlo Beevis

In fact, we've kind of already approved that strategy out with Target on the scrub program that we did. There was a big ask for some advertising dollars there that we pushed back and took on ourselves and has really been doing well for us and for the program. And they're quite happy with it. So I think we'll be successful doing that with further programs with them as well as the other retailers.

Okay, and then in July, you signed an agreement with GemStop SQ Inc. to formulate, manufacture, and commercialize active antimicrobial hard surface coating technology. Are you required to pay anything into this initiative, either capital investment, marketing, or advertising support?

Yes, we're going to foot all the development costs. We're going to pay for all testing, development. They will not charge us any fees. Obviously, all the work they do is their end of the contract, but we'll pay for all the direct costs.

Got it. And do you have any idea what the scope of that would be?

Well, it just depends how successful you are. The more we have to trial and error, the more expensive it'll be. Obviously, if we get it right straight away or in the short term, we'll obviously have a much lower cost.

And as we've done some preliminary work, we do have a decent base to start working off of. So we're hopeful it won't be too much trial and error.

I see a number of questions about scrubs, so maybe thematically we'll move into scrubs first. So if anyone has questions related to that, please add them now so we can at least keep some sort of structure to the call. So what is the status of Walmart USA adding more stores in 2026 and 2027?

Yeah, kind of same as where we were. As soon as there's space available for us, we'll add into additional stores. They have a glut of inventory from the incumbent that they're trying to move through. But all signs are still, as we've mentioned previously, that we would look to be a good part of their business in the scrubs by fall of 27.

Can I jump in here, Giancarlo? Am I correct in saying that our bigger goal is to get more shelf space?

Hylton Karon, Hilton Price, Giancarlo Beevis I think we're obviously looking to continue our international growth. We've seen that we've gone into Marks and Spencer's with our pro-techs that we announced last year. We just announced this week the expansion of our swimwear program from North America into five European countries. So yes, it is on the radar, but I think what we'll do is we'll do it through our current retail partners. Costco sells globally. Walmart sells almost globally. So we'll continue to work through those partners as we grow internationally.

And then will you consider a premium pricing for scrubs on future brands once it gets traction in the market or once EPA approval is received?

Potentially. I mean, all of that's on the table. But right now, the strategy we took to be at the more available price point seems to be working. If 60% of people in the U.S. buy their scrubs at Walmart, that's where we want to be.

And what's the current timeframe for replenishment orders for the scrubs retailers? Is it every three months? And if so, are scrubs being held in inventory for these retailers?

Scrubs is a 52-week-a-year replenishment program. So we ship scrubs every single week. And yes, we hold for Walmart anywhere between 12 and 16 weeks of stock in our warehouses.

And my understanding is that Walmart's still working through some legacy scrubs product. Do you have any update on that?

I can't answer that. I don't know. I'd love to be. I'd like to be.

I'm just going to jump in. Even if we're not the only, there's a high likelihood that we're going to supply more than one brand in the future. So, you know, there are plans to expand our opportunity there. So it might appear to look like two different suppliers, but it could very well both be us.

But we'll be the only one with a clinically proven antibacterial. So I think that's where the... The benefit is fast. Right.

And I think I just have one last question on scrubs, which is like, where are you at in the process for getting into a hospital network to purchase scrubs? And yeah, maybe you could provide an update there.

Yeah, we're still working with the Memorial Care Group, which is where we did the clinical trial. It's a cyclical thing. They have contracts that we have to wait until they expire. So we are going through the process, but we're still beginning stages of that. Once we get in there, I think it'll open up quite a few opportunities elsewhere. But in the last six months, we've been focused on executing the retail strategy that we decided was the lower hanging fruit.

Got it. And then how does the international growth playbook differ from North America? You touched on it a little bit when relating to scrubs, but I think this is more of a generic question for all brands.

Yeah, I think kind of the same way. I mean, our focus is North America because we're so entrenched in it and we have the opportunity on our doorstep within the United States and we're Those specific retailers in the US are actually coming to us with programs. So we'll deal with that first because it's on our table currently. But internationally, we'd like to grow. Obviously, there's Asda in the UK, which is the Walmart of the UK. We've had some discussions with Walmart Mexico. So it's there. It's ready to go. I think scrubs are a universal item. Everywhere needs them. So that'll obviously be one that's a key for us. But Hilton Price, Giancarlo Beevis Hilton Price, Giancarlo Beevis

Hylton Karon, Hilton Price, Giancarlo Beevis

Yeah, the answer is yes, it will correlate. And no, we don't pay commissions on all our sales. I don't believe we pay any commissions on intimate apparel. It's very specific. Intelligent fabric programs like for Walmart, where a representative or a consultant opened the door and they get continual revenue stream from us. There might be others like that in the future, but it's not every product that we sell that generates commissions. and not every product generates royalties. Obviously our own product, our own brands are royalty free.

Okay. And then is management exploring structural melt extrusion or inherent physical fiber innovations for long-term product development? Or is the strategic focus remaining strictly on proprietary chemical treatments applied to existing yarns and fabrics?

We've done both in the past. We do have some fiber technologies that we're looking at as a long-term R&D project, but we've found topical a much more integratable way of using our technologies in the market. But yes, there are some developments on the horizon for us in that realm as well.

Can you comment on sell-through as you have visibility issues?

Yeah, I mean, our scrub programs have been doing well. All of our new intimate apparel launches have been doing incredibly well. Leakproof continues to thrive, giving exact sell-throughs. I don't think we would be appreciated by our retailers. But everything is, we don't have anything that's not selling through. Let's put it that way.

And can you provide any guidance or any updates on how Nudish is doing?

It's taken off quite well. It's doing well at Target. It's doing well at Kohl's. And in fact, we're expanding that brand out to not only being the solution bra and bra accessory products. We'll be looking to launch more performance type underwear and bras coming in the future, as well as some sleepwear and some loungewear that will also bear the nudish brand. And then we have some other opportunities that we're looking at to use that brand as well.

And for Costco Roots Footwear, can you provide an update on how that program's going?

The first one's gone through and we're busy finalizing one for the following year. So that's where we're at right now.

And Roots Swimwear, is that still a program that's... Yep, continuing into next year. Yep. How would you compare the sizes of those two programs? Obviously, Footwear is larger.

We generally don't give breakdowns on what our product mix is and how that leads to revenue, but they're both substantial programs and both doing very well and look to be in for the foreseeable future.

Could you provide an update on the commercial rollout and initial retailer feedback regarding the partnership with the Ladd Collective to bring functional bedding to the North American market?

Yeah, that's something we're working on now. We expect it to be somewhere in the market in 2027. The acceptance has been obviously very good. The physical properties of the bedding itself are incredible as well as the technology that we're going to add to it. So the initial feedback has been great. We're fitting into retailer calendars to make sure we get a launch in the not so distant future.

Okay. I think that covers everything on specific programs. We saw a step in G&A expenses over Q1. What is the baseline expectation in Q3 and Q4?

Baseline? G&A expenses Our goal remains to make 15% net after G&A so I'd rather look at it that way We're not a big company, so our GNA is actually very, very manageable. I don't see massive growth in our core GNA. If there's any growth, it's going to be in variable costs related to revenue. We will be adding people, but we'll also be using AI, so maybe we'll get some kind of benefit there.

Yeah, next webinar is just chatbots, right guys?

I've been replaced by AI, you won't see me.

You and me both, Hilton. How should we think about selling expenses on a quarterly basis going forward, given the rollout of multiple new products? Will the share as a percent share of gross revenue change materially?

I don't believe so. At larger revenues, the increase will be fairly nominal.

Yeah. And can you talk about the investment in new product launches broken down by CapEx, if any, and the hard service chemicals and marketing campaigns to roll out and target internationally, etc.? ?

The investment in new product launches, I mean, we do specifically all go into the target scrubs. As Hilton had mentioned, we took on the advertising there. It wasn't a massive investment, but we used it wisely and I think probably better than ever. would have been handled in-house. For example, if we would have done it through Target, they would have put it in their marketing machine and would have been marketing to the person looking for bananas at Target who's not necessarily looking for scrubs. By handling it ourselves, we're able to focus it and really dive into the customer trying to let them know that now Target carries scrubs and how great those scrubs are. So while I can't really give you the dollar figure of what we invested, it was substantially less than what they wanted and substantially more effective than what we believe theirs would have been. When we started the scrubs at Walmart, we paid for some signage in every store where all of our scrubs went and intimate apparels. We paid for some sidekicks that go in about 1,100 Walmart stores. But again, that's real estate now we own. So it's ours for the next However long, it's not going anywhere because we paid for it. So I can't put a number on it, but there is small investments on major programs that we launch. I mean, for hard surface chemicals, it was a nominal fee that we started with. And as Hilton mentioned, we'll pay for all the direct cost testing, things of that nature. That's pretty much it. I think that's as best we can answer that.

And then on the Target Aura launch, the press release mentioned 400 stores. How should we think about the rollout across those locations? Is there an incumbent like at Walmart?

No, so we are the only... Target didn't sell scrubs before this launch. We were the only ones. They put it out to all the major scrub companies in North America to be the supply. They chose us, predicated primarily on the clinically validated study and technology that are on the scrubs. They saw the value. So those 400 stores would have launched... Almost all at the same time. They should have been at the same time, but over about a four to five week span, most of the stores get them set. And that just happened a couple months ago. So those stores should be fully set by now. We know it's doing well. We know it's continuing through next year. So now it's really just to expand, same as Walmart, expand SKU count, expand store count and continue to grow it.

How do they pick those 400 locations? Just out of curiosity, are there certain markets that they think they'll do well in? Are there certain locations that they just use to test any new products?

Typically, we get told by a retailer. With this particular program, they asked for some of our guidance as to where we would see the best value. So we put them near major medical systems, major medical schools, things of that nature. Not all of them went there because it depends on store space planning for Target. But yes, we were able to help them strategically pick some certain locations out of those 400 that we thought would benefit from having the scrubs and would possibly have more people walking into a Target looking for scrubs.

And have you thought about a B2C program for scrubs in the U.S.? Like direct-to-consumer?

Currently, no, but we'll see in the future.

And there are a lot of moving parts in the near term. Do you have an update on long-term strategy for growth beyond 2026-27? Hilton, do you want to take that or do you want me to?

Go first. Okay, sorry. I got distracted on that one. I mean, the long-term growth strategy, again, is there a lot of organic growth. We want to continue to grow in the retailers we are. We have so much ample opportunity. Scrubs at Walmart were eight SKUs in 1,400 stores. It could be 12 SKUs in 4,800 stores. So that's our focus in the near term. and it might take more than the near term to fully execute all of that and get into all those stores and fully penetrate. Obviously the same thing at Target. Scrubs is a major focus with us in all aspects. Internationally growing. I mean, having the Versus brand, regardless of what category it is, expand into five new countries is very important for us. We want to make that a prevalent brand that other retailers want to bring in and put in store. We think that the launch in Europe in-store will lead to North American in-store placement, hopefully as soon as spring of next year. So that's kind of where we are through 26 and at least through 27. Also the new product categories that we haven't announced as of yet that are not necessarily apparel. still textile based, but more hard. I want to call them hard surface, but hard product. That's a big focus on us to diversify the different categories that we're in through 26 and 27. Some cool new things launching that once we can say, we will say. I think that's pretty much it for 26, 27. We're already, believe it or not, starting to look at 28. So that's where we are.

And I think, if not on this call, on previous ones, Hilton, you've mentioned a long-term EBITDA target of 15% to 20%. When do you think that sort of comes into play for investors? Is that 28%, 29%?

It's almost looking good for this year, so we'll see how it plays out.

And at what point would you start to think about a possible dividend deal?

As soon as we need more money. No, I think we're cognizant of that. One of the problems is when we're using credit lines, that becomes difficult. If we maintain a cash situation, it could be sooner than you think, possibly within the next two years. We would like to get a dividend on the table. It might start small, but we would like to start with something.

Yeah, makes sense. I think also like you're considered high growth. So keeping cash for growth right now is probably what investors for the most part would want you to do.

Yeah, I think we're better off spending our money to develop IP because IP will create the best long-term value. Certainly, it will create a lot more interest in our company. I'm not saying we'll get bought out, but we'll have a lot more big company eyes on us. And for those big billion-dollar companies, $500 million, a billion is just a rounding difference.

Okay. What's the probability of securing sales agreements with Costco USA? I'm assuming that's specifically for scrubs.

I don't know how it relates to scrubs, but we're working on it. We signed a new license with a brand, as we noted a couple, I think it was about a month ago, that we've gotten strategically for entree into Costco US and Sam's Club in the US. So, I mean, I can shake my crystal ball and see what it says, but a high probability is my guess, but we're working on that currently.

And I think you've already talked about R&D Pipeline and new initiatives. I mean, you can't really relay any information on that one.

Can I just jump in here and say, Debra, we've got a whole lot of other technologies, some of which we haven't actually brought to the forefront to create businesses out of. So there's plenty within our current portfolio that when we start devoting some time and attention to them, they will represent growth points within the company.

It seems to be that the product pipeline seems to be a recurring theme here. So just a quick future statement, I don't know. We're working on a combination of protex with one of our other technologies called DreamSkin in a wound care environment where DreamSkin is specifically developed to help your skin heal faster. So when we combine the two products together, obviously Protex keeps the infection away while Dream Skin will help your wound heal in a faster state. That is something we're working on, on a wound care type of product. And just to give a little bit of carrot going forward, those are some of the markets that we're working on and some of the products we're working on for probably late 27, early 28.

Would something like that require another clinical trial or does the one that you've conducted sort of cover you off?

wouldn't require a clinical trial. It would require some regulatory work. But last year we announced, I believe it was last year, it could have been two years, that we registered as a medical device for some of our products. These types of products would fall under that registration and was part of why we started the medical device registration early.

Do you require any other studies in hospital studies, things like that?

We don't require, but I saw the question there, are we going to do any more? We may. I think that we will look to do something on other soft surfaces within a hospital, potentially ward curtains, potentially bed sheets, things of that nature. We do have hospital groups that are in the U.S. that are interested, Memorial Care being one. Another one that's probably the third largest healthcare system in the U.S. who has expressed interest in doing some kind of study with us. The end of the question there is to prove that the scrubs reduce infection rates as opposed to loads on the scrubs. It's all part and parcel. If you reduce the amount of bacteria living in an environment, it can directly link and there's theoretical proof that we can show that it doesn't reduce infection rates. I don't know that doing another scrub study would really help, but we would like to show it across multiple different soft surface items.

And just like in terms of your strategy for Hylton Karon, Hilton Price, Giancarlo Beevis

We'll see. We'll take on where we think we can do it well and we can do it better. And if there are other items, specifically maybe the wound carry is an opportunity where we license it to a Medline or a CardioHealth or something like that. That is an opportunity. But where we think we can do the best job, we'll keep it in-house.

And would you license some of your core technologies to new markets like Asia or LATAM or... Potentially. I mean, globally, scrubs is huge, right? But that is something you would potentially look at? Yeah. One last question, I think, and if anyone has any additional ones, feel free to jam them in there and we'll try and cover them off. So appreciate the commentary on revenue seasonality. Given Q4... I'm not sure that this is true, but they say given Q4 is expected to be the highest revenue quarter. I think that's generally seasonally, maybe not for 2026. But can you discuss how Q3 is tracking so far? I don't think you can really provide guidance, but maybe you could talk a little bit about what you're seeing for the second half of the year.

I would anticipate Q3 being mainly replenishment oriented. We may get some of the set programs start late in the quarter. Giancarlo can speak to that. Sometimes the timing doesn't always line up year on year. So it just depends at the end of the day. But as a rule, Q1 and Q4 will be our biggest quarters.

I think that Q3 will be an improvement over last year. I think we could squeeze maybe one program in. Again, it really depends on timing and when we actually ship the goods. But if it doesn't go in Q3, it'll just add to the bigger number in Q4. We like to look at the business as an annual business, not a quarter-to-quarter. That's what our goals are, is to make sure that the year-over-year numbers are where we expect them to be.

I think it's important for the investors when they're looking at our quarters to compare quarter this year to quarter last year. Don't look at Q2 and Q1 and say, well, you did so much in Q1. How does it relate to Q2? It's more important for us because of seasonality. Hylton Karon, Hilton Price, Giancarlo Beevis

And just for clarity's sakes, I think you've been very consistent all year since you reported Q1 that Q1 was an anomalous quarter. And while you don't provide formal guidance, investors should sort of look at a 20% growth quarter over quarter for the rest of the year. Is that still consistent with your messaging? Yeah.

Look at the annual and then let's look at the percentage growth and it'll be impressive. I think get out of this quarter to quarter thing. It's an annual business.

All right. Well, looks good annually so far. So what are you guys most excited about for the company? Which categories, which regions, which geographies? What makes you the most excited right now?

I think obviously Scrubs is an easy one. I think that that's one of them for sure. We're very excited about the opportunity with the hard surface. We're super excited about betting. The question about the land collective was pertinent. There's a lot of interest around it. They've done a heck of a job on their end advertising and getting it out in their markets. And we think we can really capitalize on that here. And then I think the new categories that we haven't announced yet, once we announce the market will be really excited about probably things they never thought we'd be in. But we've found a niche and we believe it'll resonate. So at least for me, that's the exciting part.

Hilton Price, Giancarlo Beevis You really changed the capitalization of the company. You've brought in some phenomenal shareholders as supporters. I think, you know, it's been a transformative year for iFabric in a number of different ways. So you should be really proud.

Thank you very much. And our aim is not to disappoint anyone.

Definitely don't disappoint me, Hilton.

I'm watching. We are going to try our best to disappoint no one.